Objectives To assess and compare subsequent hospital admissions within 30 days for
patients after receiving a prescription for either oral nirmatrelvir/ritonavir or oral molnupiravir …

We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …

In response to the COVID-19 pandemic, Merck Sharp & Dohme (MSD) acquired the global
licensing rights for the antiviral molnupiravir, promising affordable access via licensing …

Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …

Recently ERS, WHO and NIH have updated the extensive living guidelines for the treatment
of adults with COVID-19 disease, 1–3 concerning both hospitalized and nonhospitalized …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

Molnupiravir (MOV) was introduced in Israel in January 2022 during the SARS-CoV-2
Omicron surge for high-risk patients contraindicated for nirmatrelvir/ritonavir. This …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

2. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse
drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. 3. Greene HL, Graham EL, Werner …